BoltzGen Democratizes AI Therapeutic Design, Expands Druggable Universe
The open-source model designs therapeutics across "any" modality with experimental validation for diverse real-world challenging targets.
The latest Boltz open-source model designs therapeutics across "any" modality with experimental validation for diverse real-world challenging targets. By Fay Lin, PhD
Ever since Boltz-1 debuted in November 2024 as a fully commercially available AI model to achieve AlphaFold 3-level accuracy in predicting the 3D structure of biomolecular complexes, the Massachusetts Institute of Technology (MIT) research team has been on a roll, pushing forward a new standard in open-source AI-based drug discovery.
By Fay Lin, PhD
Author's summary: BoltzGen expands AI therapeutic design.
More News
- SLO County Touts Improved Public Safety with Opening of New Communications Center | News Channel 3-12
- Acres.com to collaborate with UA System’s Fryar Center - Talk Business & Politics
- Battlefield 6's Battle Royale Mode Is Called REDSEC, Is Free-To-Play, And Launches Tomorrow
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Rolls-Royce tests first high-speed methanol marine engine
- Hospital redevelopment: what the first year of construction will look like
- Eglin battalion chief and wife lose Crestview home to lightning strike, community rallies in support
- Battlefield 6 REDSEC battle royale to officially launch soon
- Why Every Venue Needs Its Own ‘Black Box’ for Public Safety
- Importing beef is not the solution | GABEL